Drugs Made In America Acquisition Corp. shares rise 2.46% premarket after UCB announces $5 billion U.S. investment.

Drugs Made In America Acquisition Corp. rose 2.46% in premarket trading. The company's stock price increase may be attributed to UCB's announcement of a significant investment in a new, state-of-the-art biologics manufacturing facility in the United States. This investment is expected to deliver an economic impact of approximately $5 billion, including the creation of 300 U.S. direct high-skilled jobs and more than 500 construction jobs.